NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its earnings results on Thursday, November, 7th. The biopharmaceutical company reported $2.11 EPS for the quarter, topping analysts' consensus estimates of $1.31 by $0.80. The biopharmaceutical company had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12 million. Lexicon Pharmaceuticals had a return on equity of 2,372.40% and a net margin of 49.78%. The firm's revenue for the quarter was up 4124.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.26) earnings per share. View Lexicon Pharmaceuticals' Earnings History.

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Lexicon Pharmaceuticals.

6 Wall Street analysts have issued twelve-month price objectives for Lexicon Pharmaceuticals' stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 114.4% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals.

Media stories about LXRX stock have been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totalling 13,580,000 shares, an increase of 17.8% from the December 31st total of 11,530,000 shares. Based on an average daily trading volume, of 1,370,000 shares, the short-interest ratio is presently 9.9 days. Currently, 13.2% of the shares of the stock are short sold. View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Progenics Pharmaceuticals (PGNX), Orexigen Therapeutics (OREX), Iovance Biotherapeutics (IOVA), Geron (GERN) and Novavax (NVAX).

Lexicon Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.35%), Strs Ohio (0.12%), California Public Employees Retirement System (0.10%) and Virginia Retirement Systems ET AL (0.03%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

LXRX stock was acquired by a variety of institutional investors in the last quarter, including Strs Ohio, Virginia Retirement Systems ET AL and California Public Employees Retirement System. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $3.27.

Lexicon Pharmaceuticals has a market capitalization of $346.97 million and generates $63.21 million in revenue each year. The biopharmaceutical company earns $-120,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.View Additional Information About Lexicon Pharmaceuticals.

The official website for Lexicon Pharmaceuticals is http://www.lexpharma.com/.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.